JBM (Healthcare) Ltd. (HK:2161)
:2161
Top Page
JBM (Healthcare) Ltd.
(2161)
Select Model
Select Model
Rating:75Outperform
Price Target:
HK$3.00
▲(8.30% Upside)
Action:ReiteratedDate:10/31/25
JBM (Healthcare) Ltd. demonstrates strong financial performance with robust revenue growth and profitability, supported by a solid balance sheet. The valuation is attractive with a reasonable P/E ratio and high dividend yield. However, technical indicators suggest a neutral market sentiment, which slightly tempers the overall score.
Positive Factors
High profitability margins
Sustained high gross and net margins plus strong EBIT/EBITDA indicate durable pricing power and operational efficiency. These margins provide recurring cash generation capacity, support investment and dividends, and make the business more resilient to cost shocks and competitive pressure over months.
Negative Factors
Decline in free cash flow growth
A near-20% drop in free cash flow growth is a structural concern if sustained: it can limit capital spending, acquisitions, and dividend sustainability despite accounting profits. Persistent FCF erosion reduces financial optionality and raises funding risk over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability margins
Sustained high gross and net margins plus strong EBIT/EBITDA indicate durable pricing power and operational efficiency. These margins provide recurring cash generation capacity, support investment and dividends, and make the business more resilient to cost shocks and competitive pressure over months.
Read all positive factors
JBM (Healthcare) Ltd. (2161) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.18B
Dividend Yield9.98%
Average Volume (3M)599.79K
Price to Earnings (P/E)5.3
Beta (1Y)0.08
Revenue Growth12.83%
EPS Growth36.12%
CountryHK
Employees279
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.14
Shares Outstanding822,000,000
10 Day Avg. Volume515,131
30 Day Avg. Volume599,792
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.36
Price to Sales (P/S)1.87
P/FCF Ratio7.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.33
Revenue Forecast (FY)HK$953.48M
JBM (Healthcare) Ltd. Business Overview & Revenue Model
Company Description
JBM (Healthcare) Limited, an investment holding company, develops, manufactures, markets, distributes, and sells healthcare and wellness products in Asia. The company offers consumer healthcare and proprietary Chinese medicines, such as over-the-c...
How the Company Makes Money
null...
JBM (Healthcare) Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 812.98M | 782.29M | 648.41M | 520.32M | 406.14M | 397.16M |
| Gross Profit | 461.42M | 413.71M | 338.08M | 187.92M | 142.30M | 180.94M |
| EBITDA | 328.56M | 298.41M | 220.73M | 111.40M | 84.14M | 114.51M |
| Net Income | 216.39M | 197.26M | 130.46M | 57.09M | 24.62M | 22.60M |
Balance Sheet | ||||||
| Total Assets | 1.77B | 1.55B | 1.39B | 1.40B | 1.33B | 1.38B |
| Cash, Cash Equivalents and Short-Term Investments | 194.20M | 205.85M | 140.81M | 152.27M | 69.84M | 94.38M |
| Total Debt | 383.18M | 171.75M | 133.41M | 180.10M | 213.09M | 267.92M |
| Total Liabilities | 640.10M | 381.16M | 366.75M | 372.10M | 363.30M | 434.25M |
| Stockholders Equity | 1.07B | 1.08B | 970.68M | 985.51M | 929.20M | 904.71M |
Cash Flow | ||||||
| Free Cash Flow | 155.61M | 205.92M | 181.00M | 137.75M | 52.96M | 35.97M |
| Operating Cash Flow | 185.60M | 226.94M | 191.22M | 145.89M | 60.01M | 58.93M |
| Investing Cash Flow | -266.90M | -120.48M | 8.31M | -7.05M | -7.57M | -24.63M |
| Financing Cash Flow | 119.83M | -41.54M | -210.72M | -56.04M | -76.85M | -13.92M |
JBM (Healthcare) Ltd. Technical Analysis
Negative
2.77
Price Trends
2.71
Negative
2.74
Negative
2.80
Negative
Market Momentum
-0.02
Positive
43.88
Neutral
65.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2161, the sentiment is Negative. The current price of 2.77 is above the 20-day moving average (MA) of 2.70, above the 50-day MA of 2.71, and below the 200-day MA of 2.80, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.88 is Neutral, neither overbought nor oversold. The STOCH value of 65.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2161.
JBM (Healthcare) Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$2.18B | 5.29 | 20.10% | 9.98% | 12.83% | 36.12% | |
69 Neutral | HK$2.38B | 5.13 | 12.97% | 15.40% | -1.88% | 17.57% | |
68 Neutral | HK$677.60M | 24.59 | 1.57% | 9.43% | -1.99% | -81.52% | |
66 Neutral | HK$1.74B | 7.90 | 5.33% | 5.16% | 2.89% | -68.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$163.16M | -4.22 | -30.35% | ― | -17.32% | 55.74% |
* Healthcare Sector Average
HK:2161
JBM (Healthcare) Ltd.
2.65
1.23
86.62%
HK:1498
PuraPharm Corp. Ltd.
0.31
-0.20
-39.00%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.16
0.14
13.73%
HK:2633
Jacobson Pharma Corporation Limited
1.25
0.27
27.55%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.80
0.00
0.00%
JBM (Healthcare) Ltd. Corporate Events
JBM Healthcare and Jacobson Pharma Renew Connected Logistics Framework Through 2029
Mar 6, 2026
JBM (Healthcare) Limited and Jacobson Pharma Corporation have renewed their framework agreements governing continuing connected transactions, putting in place new arrangements that will run from 1 April 2026 to 31 March 2029. The deals include a 2...
JBM Healthcare to Appoint Chairman Derek Sum as CEO Following Patrick Wong’s 2026 Exit
Jan 30, 2026
JBM (Healthcare) Limited has announced that Chief Executive Officer Patrick Wong Yat Wai will step down with effect from 30 April 2026 to pursue other career opportunities, with the board noting there is no disagreement or issues requiring shareho...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.